“We feel good about our assumptions around the $75 million to $100 million headwind there in China, and that's only been validated by what we've seen in China here in the first quarter, even if the patient volumes were actually a little higher.”

How to check this claim

Look at: Full-year revenue headwind attributed to China (as disclosed by management), fiscal year 2026

It came true if: Reported/reaffirmed China headwind falls within $75 million to $100 million

Where: Company earnings call commentary and investor presentations (Q2-Q4 2026 calls, FY2026 10-K)

Verify independently

SEC filings for DHR ↗ · Claim quote is verbatim from the 2026Q1 earnings call.